Design and synthesis of [(2,3-dichlorophenyl)piperazin-1-yl]alkylfluorenylcarboxamides as novel ligands selective for the dopamine D3 receptor subtype
- PMID:11543687
- DOI: 10.1021/jm010146o
Design and synthesis of [(2,3-dichlorophenyl)piperazin-1-yl]alkylfluorenylcarboxamides as novel ligands selective for the dopamine D3 receptor subtype
Erratum in
- J Med Chem 2002 Aug 29;45(18):4056
Abstract
The dopamine D3 receptor subtype has been recently targeted as a potential neurochemical modulator of the behavioral actions of psychomotor stimulants, such as cocaine. However, definitive behavioral investigations have been hampered by the lack of highly selective D3 agonists and antagonists. In an attempt to design a novel class of D3 ligands with which to study this receptor system, a series of chemically divergent compounds that possessed various structural features that exist within several classes of reputed D3 agents was screened and compared to the recently reported NGB 2904 (58b). On the basis of these results, a novel series of compounds was designed that included functional moieties that were required for high-affinity and selective binding to D3 receptors. All the compounds in this series included an aryl-substituted piperazine ring, a varying alkyl chain linker (C3-C5), and a terminal aryl amide. The compounds were synthesized and evaluated in vitro for binding in CHO cells transfected with human D2, D3, or D4 receptor cDNAs. D3 binding affinities ranged from K(i) = 1.4 to 1460 nM. The most potent analogue in this series, 51, demonstrated a D3/D2 selectivity of 64 and a D3/D4 selectivity of 1300. Structure-activity relationships for this class of ligands at D3 receptors will provide new leads toward the development of highly selective and potent molecular probes that will prove useful in the elucidation of the role D3 receptors play in the psychomotor stimulant and reinforcing properties of cocaine.
Similar articles
- Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor.Grundt P, Carlson EE, Cao J, Bennett CJ, McElveen E, Taylor M, Luedtke RR, Newman AH.Grundt P, et al.J Med Chem. 2005 Feb 10;48(3):839-48. doi: 10.1021/jm049465g.J Med Chem. 2005.PMID:15689168
- N-(4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl, butenyl and butynyl)arylcarboxamides as novel dopamine D(3) receptor antagonists.Newman AH, Cao J, Bennett CJ, Robarge MJ, Freeman RA, Luedtke RR.Newman AH, et al.Bioorg Med Chem Lett. 2003 Jul 7;13(13):2179-83. doi: 10.1016/s0960-894x(03)00389-5.Bioorg Med Chem Lett. 2003.PMID:12798330
- Heterocyclic analogues of N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)arylcarboxamides with functionalized linking chains as novel dopamine D3 receptor ligands: potential substance abuse therapeutic agents.Grundt P, Prevatt KM, Cao J, Taylor M, Floresca CZ, Choi JK, Jenkins BG, Luedtke RR, Newman AH.Grundt P, et al.J Med Chem. 2007 Aug 23;50(17):4135-46. doi: 10.1021/jm0704200. Epub 2007 Aug 2.J Med Chem. 2007.PMID:17672446
- Dopamine D3 receptor ligands with antagonist properties.Hackling AE, Stark H.Hackling AE, et al.Chembiochem. 2002 Oct 4;3(10):946-61. doi: 10.1002/1439-7633(20021004)3:10<946::AID-CBIC946>3.0.CO;2-5.Chembiochem. 2002.PMID:12362359Review.
- Progress in developing D3 dopamine receptor ligands as potential therapeutic agents for neurological and neuropsychiatric disorders.Luedtkea RR, Mach RH.Luedtkea RR, et al.Curr Pharm Des. 2003;9(8):643-71. doi: 10.2174/1381612033391199.Curr Pharm Des. 2003.PMID:12570797Review.
Cited by
- N-(4-{4-[2-(Trifluoro-meth-oxy)phen-yl]piperazin-1-yl}but-yl)thio-phene-2-carboxamide dihydrate.Cai J.Cai J.Acta Crystallogr Sect E Struct Rep Online. 2010 Dec 15;67(Pt 1):o125. doi: 10.1107/S160053681005155X.Acta Crystallogr Sect E Struct Rep Online. 2010.PMID:21522636Free PMC article.
- Evaluation of N-phenyl homopiperazine analogs as potential dopamine D3 receptor selective ligands.Li A, Mishra Y, Malik M, Wang Q, Li S, Taylor M, Reichert DE, Luedtke RR, Mach RH.Li A, et al.Bioorg Med Chem. 2013 Jun 1;21(11):2988-98. doi: 10.1016/j.bmc.2013.03.074. Epub 2013 Apr 6.Bioorg Med Chem. 2013.PMID:23618707Free PMC article.
- 2016 Philip S. Portoghese Medicinal Chemistry Lectureship: Designing Bivalent or Bitopic Molecules for G-Protein Coupled Receptors. The Whole Is Greater Than the Sum of Its Parts.Newman AH, Battiti FO, Bonifazi A.Newman AH, et al.J Med Chem. 2020 Mar 12;63(5):1779-1797. doi: 10.1021/acs.jmedchem.9b01105. Epub 2019 Sep 24.J Med Chem. 2020.PMID:31499001Free PMC article.
- The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence.Heidbreder CA, Gardner EL, Xi ZX, Thanos PK, Mugnaini M, Hagan JJ, Ashby CR Jr.Heidbreder CA, et al.Brain Res Brain Res Rev. 2005 Jul;49(1):77-105. doi: 10.1016/j.brainresrev.2004.12.033.Brain Res Brain Res Rev. 2005.PMID:15960988Free PMC article.Review.
- YQA14: a novel dopamine D3 receptor antagonist that inhibits cocaine self-administration in rats and mice, but not in D3 receptor-knockout mice.Song R, Yang RF, Wu N, Su RB, Li J, Peng XQ, Li X, Gaál J, Xi ZX, Gardner EL.Song R, et al.Addict Biol. 2012 Mar;17(2):259-73. doi: 10.1111/j.1369-1600.2011.00317.x. Epub 2011 Apr 20.Addict Biol. 2012.PMID:21507153Free PMC article.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Chemical Information
Miscellaneous